



CLINICAL PHARMACOLOGY SHARED RESOURCE

The Clinical Pharmacology Shared Resource (CPSR) provides critical scientific and technical support for the development and performance of clinical trials as well as the dissemination of the trial results. This support is essential for early phase clinical trials, including first-in-human studies, but also adds significant value to clinical trials focused on new applications and new combinations of current therapeutics. The guidance and support from the CPSR ensures that clinical trials are comprehensive, driving the development and advancement of therapeutic and preventative approaches for cancer.

WHY IS THIS IMPORTANT TO YOUR RESEARCH?

Clinical pharmacology is the study of drugs in humans. Imperative to the advancement of new and improved drugs, clinical pharmacology helps researchers better understand dose-exposure and dose-response relationships, drug-drug interactions and drug effectiveness and safety in humans, bridging the gap between the lab and clinic.

SERVICES

The CPSR provides essential support for studies in cancer therapeutics, cancer prevention and cancer population studies. It is comprised of three interacting components:

1. The correlative laboratory, which provides GCP-compliant (i.e., good clinical practice) acquisition, processing, and storage or shipping of clinical research samples.
2. The Bioanalytical Laboratory, a GLP-like (good laboratory practice) fit-for-purpose facility that prepares biological fluids, cells or tissue samples and analyzes them for concentrations of drugs, drug metabolites and other small molecule biomarkers.
3. The pharmacokinetics/pharmacodynamics unit in which members of the CPSR team – who specialize in cancer therapeutics – perform calculations and modeling to define and interpret the kinetics of drugs and their actions.

LOCATIONS

Offices, main correlative laboratory and bioanalytical laboratory are on the second floor of the KU Clinical Research Center. Additional correlative laboratories are located at The University of Kansas Hospital and Bloch Cancer Pavilion.

LEARN MORE

Paul Toren, PhD, Director
ptoren@kumc.edu
913-945-8727

Was your research supported by KU Cancer Center's NCI Cancer Center Support Grant? If so, please use the following statement in all of your published materials: *Research reported in this publication was supported by the National Cancer Institute Cancer Center Support Grant P30 CA168524 and used the [name of the CCSG Shared Resource(s), if applicable].*